TGA Peptide Regulation: Australia Legal Status Guide
James MitchellMSc Biochemistry Australian Peptide Regulation Overview
Australia has one of the more structured regulatory environments for peptide therapy, administered by the Therapeutic Goods Administration (TGA) under the Therapeutic Goods Act 1989.
The Scheduling System
The TGA classifies substances under the Poisons Standard. Peptide products can be treated differently depending on the substance, route, dosage form, claim, and whether the product is an approved or unapproved therapeutic good.
Schedule 4 — Prescription Only Medicine
Where a peptide medicine is Schedule 4, the prescription-only framework generally means:
- They can only be legally obtained with a valid prescription
- Prescriptions must be written by a registered medical practitioner
- Pharmacies may only supply within the relevant prescription, compounding, and state or territory rules
- Supply without prescription is an offence under state and territory laws
Product-Claim Differences
Some peptides in specific formulations may have different scheduling:
- GHK-Cu in topical cosmetic products may be treated differently from injectable or therapeutic-use products
- Peptide-based supplements or cosmetics can fall under different rules when no therapeutic claim is made
- Unapproved therapeutic goods may require Special Access Scheme, Authorised Prescriber, clinical trial, or personal importation analysis
Access Pathways
Authorised Prescriber Scheme
The TGA’s Authorised Prescriber (AP) scheme allows a named medical practitioner to access an unapproved therapeutic good for a class of patients with the same condition. Under this scheme:
- A registered medical practitioner applies through the TGA process for a specified unapproved therapeutic good and indication
- Once authorised, the practitioner may access the specified unapproved good for the approved class of patients
- The practitioner assumes responsibility for monitoring and reporting
- Authorisation is specific to the practitioner and the substance
Special Access Scheme (SAS)
For individual patient access:
- Category A (SAS-A): For seriously ill patients — notification only
- Category B (SAS-B): Requires TGA approval before supply — used for most peptide access
- Category C: Available for specified products without individual approval
Compounding Pharmacies
Australian compounding and dispensing pathways sit across TGA rules, state and territory medicines and poisons laws, and pharmacy-board requirements:
- Pharmacies must hold appropriate registration or licences
- Prescription-only medicines require a valid prescription
- State and territory rules may add requirements for supply, storage, dispensing, and recordkeeping
- TGA access pathways still matter when the product is an unapproved therapeutic good
Personal Importation
The TGA’s Personal Importation Scheme allows individuals to import many therapeutic goods for personal use when all conditions are met:
- The product must be for personal use or immediate family use and must not be supplied to others
- A maximum three-month supply applies per import
- If the medicine is prescription-only in Australia, the importer must hold a valid Australian prescription or written authority at the time of importation
- Counterfeit products are prohibited regardless of prescription status
Sports and Sport Integrity Australia
Sport Integrity Australia applies anti-doping rules aligned with the WADA Prohibited List. Athletes should assume that non-approved research peptides, growth-hormone secretagogues, growth factors, and related substances can be prohibited at all times unless their anti-doping authority confirms otherwise.
Primary Sources
- TGA unapproved therapeutic goods overview
- TGA Personal Importation Scheme
- TGA Authorised Prescriber pathway
- TGA Special Access Scheme pathway